AVADEL PHARMACEUTICALS PLC
Customers
3
3 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Dec 31, 2024
10-K filed 2025-03-03
Customers 3
Companies AVADEL PHARMACEUTICALS PLC discloses as major customers, as a share of AVADEL PHARMACEUTICALS PLC revenue. 3 active, 0 lapsed.
| Company | % of AVADEL PHARMACEUTICALS PLC revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ACCREDO HEALTH INC ACCREDO HEALTH INC |
Named | — | FY 2024-12-31 | — | Active | 10-K 2025-03-03 |
Accredo Health Group, Inc. (“Accredo”), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 22% of gross accounts receivable. Accredo Health Group, Inc. (“Accredo”), which accounted for 28% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 20% of gross accounts receivable. | ||||||
| CVS CVS HEALTH Corp |
Named | — | FY 2024-12-31 | — | Active | 10-K 2025-03-03 |
As of December 31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (“Caremark”), which accounted for 53% of gross accounts receivable; | ||||||
| Optum Frontier Therapies LLC Non-SEC Optum Frontier Therapies LLC |
Named | — | FY 2024-12-31 | — | Active | 10-K 2025-03-03 |
Accredo Health Group, Inc. (“Accredo”), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 22% of gross accounts receivable. Accredo Health Group, Inc. (“Accredo”), which accounted for 28% of gross accounts receivable; and Optum Frontier Therapies LLC (“Optum”), which accounted for 20% of gross accounts receivable. | ||||||
Alerts are coming
Get an email when AVADEL PHARMACEUTICALS PLC's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.